Latest News

Monday, March 02, 2015 | Santen

EMA Accepts Santan's Marketing Application Filing for Intravitreal Sirolimus for the Treatment of Noninfectious Uveitis of the Posterior Segment

Santen Pharmaceutical announced that the European Medicines Agency (EMA) has accepted the company’s marketing authorization application (MAA) filing for the use of intravitreal sirolimus, an inv…

Read the full story

Monday, March 02, 2015 | Clearside Biomedical

Clearside Biomedical Initiates Phase 2 Clinical Trial for Macular Edema Associated with Retinal Vein Occlusion Drug Candidate

Clearside Biomedical announced the enrollment of the first patient in a phase 2, randomized, controlled, masked, multicenter clinical trial for the treatment of macular edema associated with retinal v…

Read the full story

Monday, March 02, 2015 | Clinical Trials, Ohr Pharmaceutical

Ohr Pharmaceutical Announces Additional Positive Anatomic Data From the OHR-102 IMPACT Study Interim Analysis Presented at Annual Macula Society Meeting

Ohr Pharmaceutical announced the presentation of new data from the IMPACT study interim analysis at the 38th Annual Macula Society Meeting, which took place February 25-28, in Scottsdale, Arizona. The…

Read the full story

Monday, March 02, 2015 | Management/Leadership

Eyegate Pharmaceuticals Names Michael B. Raizman, MD, Consulting Chief Medical Officer

Eyegate Pharmaceuticals announced the appointment of Michael B. Raizman, MD, as the Consulting Chief Medical Officer. Dr. Raizman began working with the company as a consultant in the fourth quarter o…

Read the full story

Monday, March 02, 2015 | Shire

Shire Submits Application to the FDA for Approval of Lifitegrast For Treatment of Dry Eye Disease in Adults

Shire announced that the company has submitted a new drug application with the FDA for its investigational compound lifitegrast for the treatment of signs and symptoms of dry eye disease in adul…

Read the full story

Monday, March 02, 2015 | Clinical Trials

Implandata: First Keratoprosthesis Patient in Europe Receives Permanent Intraocular Pressure Sensor EyeMate

Implandata Ophthalmic Products announced the successful implantation of Implandata’s EyeMate intraocular pressure sensor on a first patient in Europe undergoing keratoprosthesis surgery, accordi…

Read the full story

Friday, February 27, 2015 | Clinical Trials, Alcon

Phase 2 Data Highlights Benefits of Alcon's RTH258 for Patients with Wet AMD

Alcon presented results from its second phase 2 clinical study of RTH258 during the 38th Annual Macula Society Meeting in Scottsdale, Arizona. The study evaluated the efficacy and safety of the compou…

Read the full story

Friday, February 27, 2015 | Acquisitions/Mergers, Optos

Nikon to Acquire Optos for $400 Million in Cash

Nikon Corp. has agreed to acquire retinal imaging firm Optos for $400 million (259.3 million pounds) in cash, the companies announced Friday. Under terms of the agreement, Nikon will pay 340 pence a s…

Read the full story

Friday, February 27, 2015 | Earnings & Financials

Ocata Therapeutics Approved for Listing on NASDAQ

Ocata Therapeutics, a clinical stage biotechnology company developing regenerative ophthalmology therapeutics, announced that it has received notice that the NASDAQ Listing Qualifications Department h…

Read the full story

Friday, February 27, 2015 | Retina, Regeneron Pharmaceuticals

Eylea Receives EU Approval for the Treatment of Visual Impairment Due to Macular Edema Secondary to Retinal Vein Occlusion

Regeneron Pharmaceuticals announced that Eylea (aflibercept) injection has been approved by the European Commission for the treatment of visual impairment due to macular edema secondary to retinal vei…

Read the full story

Friday, February 27, 2015 | Medical Studies

New Diagnostic Test Proposed for Myasthenia Gravis

Ocular vestibular-evoked myogenic potentials could be the basis of a new test for myasthenia gravis, according to the results of a recent study. "We're very excited because it's a simple …

Read the full story

Friday, February 27, 2015 | Medical Studies

Generic Drug Use Shown to Improve Medication Adherence in People with Glaucoma

In the first study to examine the impact of a reduction in glaucoma medication copay on patient adherence, researchers in Michigan have found a potential solution to one of the biggest obstacles facin…

Read the full story

Thursday, February 26, 2015 | FDA Approval/Clearance

Lupin Receives FDA Approval for Generic Lumigan Ophthalmic Solution 0.03%

Pharma Major Lupin Limited (Lupin) announced that it has received final approval for its bimatoprost ophthalmic solution, 0.03% from the FDA to market a generic version of Allergan's Lumigan Ophth…

Read the full story

Thursday, February 26, 2015 | Product Releases, Carl Zeiss Meditec

Zeiss Launches Humphrey Field Analyzer 3 Visual Field Testing System

At the American Glaucoma Society 2015 annual meeting in Coronado, California, Zeiss is announcing the global launch of the Humphrey Field Analyzer 3 (HFA3), the next generation in visual field t…

Read the full story

Thursday, February 26, 2015 | Miscellaneous

Envision Receives $300K Mabee Challenge Grant for Research Institute

Envision announced that it has received a $300,000 challenge grant from the Tulsa, Oklahoma-based J.E. and L.E. Mabee Foundation, which will support renovation of an entire floor of Envision’s W…

Read the full story
Load More
 Stock Price  Change 
 Aerie Pharmaceuticals, Inc. $28.93  2.88% 
 Akorn, Inc. $53.71  -0.19% 
 Alimera Sciences, Inc. $5.20  -0.57% 
 Allergan, Inc. $235.80  1.31% 
 Avalanche $36.80  1.71% 
 Bayer $148.06  0.23% 
 Can-Fite Biopharma $4.65  3.33% 
 Carl Zeiss Meditec $24.50  -0.28% 
 Cooper Companies, Inc. $165.73  1.07% 
 Escalon Medical Corp. $1.52  4.82% 
 Essilor International $116.50  0.00% 
 Imprimis Pharmaceuticals, Inc. $7.87  4.93% 
 InSite Vision, Inc. $0.21  7.61% 
 IRIDEX Corporation $10.43  -2.07% 
 Johnson & Johnson $103.22  0.69% 
 LCA-Vision Inc. $5.37  0.00% 
 Luxottica Group, S.p.A. $63.95  4.43% 
 Merck & Company, Inc. $58.58  0.07% 
 NicOx $2.16  1.98% 
 NovaBay Pharmaceuticals, Inc. $0.60  11.11% 
 Novartis AG Common Stock $100.07  -2.28% 
 Ocular Therapeutix $35.52  -0.70% 
 Ophthotech Corporation $53.95  0.40% 
 Quantel $3.40  -1.73% 
 Regeneron $418.44  1.11% 
 Roche $33.99  -0.42% 
 STAAR Surgical Company $6.82  -0.58% 
 TearLab Corporation $2.61  0.38% 
 Thrombogenics $8.50  0.24% 
 Topcon Corporation $19.85  0.00% 
 Valeant Pharmaceuticals $203.35  2.97% 
 Xoma $3.74  1.36%